Clarus Therapeutics Defeats Lipocine s Patent Infringement Lawsuit On Summary Judgment
US District Court for the District of Delaware grants Clarus s Motion for Summary Judgment against remaining patents in patent infringement case brought by Lipocine, Inc. regarding Clarus s oral testosterone replacement product JATENZO®
News provided by
Share this article
Share this article
NORTHBROOK, Ill., May 25, 2021 /PRNewswire/ Today, Federal Circuit Judge William C. Bryson, a Senior Circuit Judge of the U.S. Court of Appeals for the Federal Circuit, sitting by designation in the U.S. District Court for the District of Delaware, granted Clarus s motion for summary judgment against Lipocine, Inc. ( Lipocine ;NASDAQ: LPCN) for failure to provide adequate written description of Lipocine s asserted patent claims. In his decision, which gives Clarus an unequivocal win, Judge Bryson found all of the asserted Lipocine patent claims invalid. Clarus s defense of inequitable conduct, to be
Clarus Therapeutics Defeats Lipocine s Patent Infringement Lawsuit On Summary Judgment prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics
News provided by
Share this article
Share this article
SALT LAKE CITY, Dec. 29, 2020 /PRNewswire/ Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge William C. Bryson of the United States District Court of Delaware has postponed the February 8, 2021 jury trial scheduled to hear arguments in the patent litigation case of
Lipocine Inc. vs. Clarus Therapeutics Inc. due to the ongoing effects of the COVID-19 pandemic. The jury trial will be rescheduled once it becomes clear when jury trials will resume in the District of Delaware.